Lumateperone and Prochlorperazine interaction
Lumateperone and Prochlorperazine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Lumateperone (CAPLYTA) label · effective 2025-06-20
Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs.
Seizures Like other antipsychotic drugs, CAPLYTA may cause seizures.
Potential for Cognitive and Motor Impairment CAPLYTA, like other antipsychotics, may cause somnolence and has the potential to impair judgment, thinking, and motor skills.
Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature.
From the Prochlorperazine (PROCHLORPERAZINE MALEATE) label · effective 2025-07-09
To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with prochlorperazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered, or drug therapy discontinued.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.